DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
September 14th 2021An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
Read More
Disease Recurrence Not Significantly Delayed With Panvac Plus BCG in Advanced NMIBC
September 13th 2021n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.
Read More
Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 13th 2021Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.
Read More
Aveluamab With BCG Induction Shows Early Safety/Tolerability in BCG-Unresponsive NMIBC
September 13th 2021Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Read More
Regardless of Prior Antiandrogen Therapy in mHSPC, Enzalutamide/ADT Maintains Efficacy
September 12th 2021Regardless of prior antiandrogen therapy and its pretreatment duration, enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer.
Read More
The Relevance of MFS as a Primary End Point in the ARAMIS Trial
September 12th 2021Neal Shore, MD, FACS, discusses the use of metastases-free survival as the primary end point in the ARAMIS trial, which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
Watch
Checkpoint Blockade Response Linked With MSI-H/dMMR Prostate Cancer
September 11th 2021Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.
Read More
Addressing Racial Disparities in T-Cell Lymphoma Requires Look at Social Inequity
September 11th 2021Disparities not only are widening among racial groups, but socioeconomic inequities should also be considered and addressed by the wider healthcare community, according to a lymphoma expert.
Read More
Relugolix Does Not Improve Castration Resistance-Free Survival in Advanced Prostate Cancer
September 11th 2021In the phase 3 HERO trial of relugolix versus standard of care leuprolide in men with advanced prostate cancer, relugolix failed to significantly delay onset of castration resistance.
Read More
N-803 in Combination With BCG Yields Encouraging Responses in BCG-Unresponsive Bladder Cancer
September 10th 2021Patients with BCG-unresponsive, non-muscle invasive bladder cance carcinoma in situ had promising responses to Bacille Calmette-Guérinplus N-803, updated data from cohort A of the phase 2/3 QUILT-3.032 study.
Read More
Elevated Antibody Titers May Be a Prognostic Marker in BCG-Unresponsive NMIBC
September 10th 2021According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.
Read More
Exploring CAR T-Cell Therapies in the Indolent Lymphoma Setting
September 10th 2021Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.
Read More
IGHV and TP53 Remain Important Prognostic CLL Biomarkers
September 9th 2021IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.
Read More